ETNB 89bio Inc Total Asset Value of Company

ETNB (89bio Corp) - company brandmark

89bio, Inc. is implementing digital platforms and biochemical screening to accelerate the development of metabolic drugs. This total assets chart visualizes capital density, with 592.85 setting the current value of the metric. Business stability relies on FDA approvals and the success of clinical trials. A professional R&D team, aligned through stock options, ensures the company's growth without personnel losses.

ETNB (89bio, Inc.) Company Total Assets history from 07/04/2022 to 11/15/2025

Analytical breakdowns and data insights for company 89bio Corp (ETNB)

- share price and consensus valuation forecast:
Price Chart 89bio.com|ETNB - Price Target Chart
- market capitalization data:
Market Valuation 89bio Pharma|ETNB - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share 89bio|ETNB - Book Capitalization|Market Capitalization to Book Value Ratio 89bio.com|ETNB - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio 89bio, Inc.|ETNB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio 89bio Pharma|ETNB - Company Aggregate Debts|Debts to Book Capitalization 89bio Pharma|ETNB - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 89bio|Quick Liquidity Indicator 89bio.com
- net income and valuation multiples indicators:
ETNB - Net Profit
Fundamental valuation:89bio, Inc.
Manufactured products of 89bio, Inc.

For stress-testing positions, it is critical for the investor to evaluate the aggregate of assets and liabilities, calculated reversely via ROA, to determine the company's actual resource base. Given that 89bio, Inc. (ETNB) operates within the safe haven of the pharmaceutical humanitarian sector, the change in controlled resources on the GURU.Markets platform demonstrates the business's fundamental resilience to geopolitical risks and the efficiency of asset capitalization for long-term development.

Key competitors

ASND (ascendispharma.com) - Aggregate Company Assets|Aggregate Company Assets Madrigal Pharmaceuticals, Inc.|Corcept Therapeutics Inc. - Total Asset Value of Company|Company Total Assets RYTM|AKRO (Akero Corp) - Aggregate Asset Value|Company Total Assets MTSR (Metsera Inc)|Company Total Assets moonlaketx.com MLTX|CRNX - Aggregate Company Assets|Aggregate Asset Value NAMS (NewAmsterdam Pharma Company)|Soleno (SLNO) - Aggregate Company Assets|Cumulative Company Assets Amicus Corp|AGIO (Agios Pharmaceuticals) - Company Total Assets|Company Total Assets structuretx.com|Cumulative Company Assets MDXG (MiMedx)|RZLT (Rezolute Inc) - Aggregate Asset Value|Aggregate Company Assets Lexicon Pharma LXRX|MBX - Cumulative Company Assets|Altimmune, Inc. - Company Total Assets|Company Assets aardvarktherapeutics.com|SGMT (Sagimet Biosciences Inc.) - Cumulative Company Assets|BIOA: Aggregate Business Assets|BMEA (Biomea) - Company Total Assets|Company Total Assets Quince|Company Total Assets GUTS|Aggregate Company Assets VTVT (vtvtherapeutics.com)|Aggregate Company Assets Agape ATP ATPC|Pluristem Therapeutics (PLUR) - Company Assets|SYBX - Aggregate Company Assets|LPCN: Aggregate Company Assets|MTNB: Company Total Assets|SPRB - Company Total Asset Base|Aggregate Company Assets Galecto|Carmell Corp. (CTCX) - Company Total Asset Base|Aggregate Company Assets Lumos Pharma Corp (LUMO)|Cumulative Company Assets Organovo Corp ONVO|Aggregate Asset Value Radius Recycling, Inc.